Similar articles

• PERISCOPE: pioglitazone offers the right cluster of effects to confer benefit in type 2 diabetes.

  [No authors listed] [No authors listed] Cardiovasc J Afr. 2008 May-Jun;19(3):159-62. Cardiovasc J Afr. 2008. PMID: 18568180 No abstract available.
• Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.

  Nicholls SJ, Tuzcu EM, Wolski K, Bayturan O, Lavoie A, Uno K, Kupfer S, Perez A, Nesto R, Nissen SE. Nicholls SJ, et al. J Am Coll Cardiol. 2011 Jan 11;57(2):153-9. doi: 10.1016/j.jacc.2010.06.055. J Am Coll Cardiol. 2011. PMID: 21211686 Clinical Trial.
• Seeking alternatives to Hard End Points: is imaging the best APPROACH?

  Finn AV, Chandrashekhar Y, Narula J. Finn AV, et al. Circulation. 2010 Mar 16;121(10):1165-8. doi: 10.1161/CIR.0b013e3181d83b4f. Epub 2010 Mar 1. Circulation. 2010. PMID: 20194886 No abstract available.
• CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.

  Betteridge DJ. Betteridge DJ. Fundam Clin Pharmacol. 2009 Dec;23(6):675-9. doi: 10.1111/j.1472-8206.2009.00741.x. Epub 2009 Sep 10. Fundam Clin Pharmacol. 2009. PMID: 19744248 Review.
• [Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive Study and PERISCOPE Study].

  Kawamori R. Kawamori R. Nihon Rinsho. 2010 Feb;68(2):235-41. Nihon Rinsho. 2010. PMID: 20158090 Review. Japanese.